Bracket Global Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Wayne PA United States (2001)

Organization Overview

First Clinical Trial
2014
NCT02230904
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Bracket Global | Bracket, Inc. | Pharmaceutical Health Sciences

Active Ingredients

Drugs in Phase 3 Trials (3)

cycloserine (seromycin) (2 trials)

ketamine (ketalar) (1 trial)

lurasidone (latuda) (2 trials)

Drugs in Phase 2 Trials (2)

niacin (1 trial)

psilocybin (1 trial)

Drugs in Phase 1 Trials (1)

rotigotine (neupro) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Bipolar Disorder (Phase 3)

Depression (Phase 3)

Depressive Disorder (Phase 3)

Depressive Disorder, Major (Phase 2)

Parkinson Disease (Phase 1)

Suicidal Ideation (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 5
  • # of Trial APIs: 6